OBX (OBX) Stock Analysis

$16.820

-0.266 (-1.58%)At close

Loading chart…

High: 19.000
Open: 17.260
VWAP: 17.46
Vol: 140.12K
Mkt Cap: —
Low: 16.570
Amount: 2.45M
EV/EBITDA, TTM: 0.00

Obsidian Therapeutics, Inc. is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE technology is designed to regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Its lead clinical program, OBX-115, is an investigational TIL cell therapy engineered to express membrane-bound IL15 (mbIL15), which is designed to support TIL activity. Its cytoDRiVE discovery platform has identified a library of internally discovered drug-responsive domains (DRDs) of varying sizes and intended purposes and enables rapid optimization of regulatable and functional proteins in any cell type. It has developed a synthetic biology engineering toolkit that supports the design and optimization of a range of therapeutic proteins, including but not limited to type I/II membrane proteins, and membrane-bound cytokines.

AI analysis of OBX (OBX)

sell

Galera Therapeutics Inc is not a good buy right now due to its significant recent decline and negative financial metrics. The stock has dropped 18.09% in the last five days and 34.80% year-to-date. Additionally, the price-to-earnings ratio is -12.68, indicating negative earnings, which raises concerns about profitability. Although analysts have positive ratings, the lack of a concrete price target from TD Cowen and the substantial drop in price suggest caution.

Valuation Metrics

The current forward P/E ratio for OBX (OBX) is 0.00, compared to its 5-year average forward P/E of .

Forward P/E

5Y Average P/E

Current P/E

0.00

Forward EV/EBITDA

5Y Average EV/EBITDA

Current EV/EBITDA

0.00

Forward P/S

5Y Average P/S

Current P/S

0.00

Events Timeline

2026-08-28 (ET)